Overview Latest Regional Industry Featured Multimedia Other Languages Public Company News
All APAC Global
All APAC Global
All APAC Global
All APAC Global
Harbour BioMed Announces First Patient Dosed in Phase I Study of First-in-Class Anti-B7H7 (HHLA2) Antibody HBM1020 2023-06-05 09:01
Harbour BioMed Reports Results of Phase Ib Clinical Trial of Porustobart in Combination of Toripalimab in Patients with Hepatocellular Carcinoma at ASCO 2023 2023-05-29 09:42
Nona Biosciences Announces Strategic Collaboration Agreement with PharmaEssentia Innovation Research Center 2023-05-12 09:32
Nona Biosciences and Washington University Join Forces to Tackle Emerging RNA Viruses 2023-04-19 08:45
Nona Biosciences Enters into Collaboration Agreement with ExeVir Bio 2023-04-06 10:20
Harbour BioMed Reports Full Year 2022 Financial Results 2023-04-03 15:10
Harbour BioMed Announces Positive Topline Results from Phase III Trial of Batoclimab for Treatment of Generalized Myasthenia Gravis 2023-03-06 14:27
HBM Alpha Therapeutics Raises Seed Round to Advance Next-Gen Therapies for Endocrine Disorders 2023-01-26 09:22
Nona Biosciences Enters into HCAb Based Drug Discovery Collaboration Agreement with Dragonfly Therapeutics 2022-11-21 17:31
Nona Biosciences Announces Attendance at PEGS Europe 2022 2022-11-15 15:57
HARBOUR BIOMED LAUNCHES NONA BIOSCIENCES' "IDEAS TO IND" PRECLINICAL SOLUTIONS BUSINESS TO ACCELERATE GLOBAL BIOTHERAPEUTIC INNOVATION 2022-11-15 12:19
Harbour BioMed Enters into a License and Collaboration Agreement with Moderna 2022-11-11 09:03
Harbour BioMed Announces Dosing of First Patient in Phase I Trial of B7H4x4-1BB Bispecific Antibody in the United States 2022-10-20 16:20
Harbour BioMed Announces Upcoming Poster Presentations at the 37th Society for Immunotherapy of Cancer Annual Meeting 2022-10-13 19:05
Harbour BioMed Announces First Subject Dosed in Phase I Study of Next-Gen Anti-TSLP Fully Human Monoclonal Antibody 2022-09-27 21:40
Harbour BioMed to Announce 2022 Interim Results on August 31, 2022 2022-08-09 15:00
PNAS Published Preclinical Results of Harbour BioMed's Next-Generation Fully Human Heavy-chain Antibody Porustobart 2022-08-08 17:43
Harbour BioMed Announces IND Clearance for B7H4x4-1BB Bispecific Antibody by the U.S. Food and Drug Administration 2022-06-27 19:04
Harbour BioMed Announces IND Approval for B7H4x4-1BB Bispecific Antibody 2022-06-08 18:11
Harbour BioMed Reports the Latest Progress of Next-Generation Fully Human Heavy-chain Antibody HBM4003 with Unique Treg Depletion Mechanism 2022-06-01 21:24
1 2 3 4